Online inquiry

IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11564MR)

This product GTTS-WQ11564MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11564MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8457MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ2290MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ950MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ3362MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ5693MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ11211MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ8018MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ11015MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-117
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW